NasdaqGS - Nasdaq Real Time Price USD

Adaptimmune Therapeutics plc (ADAP)

0.2602

-0.0021

(-0.80%)

At close: April 23 at 4:00:01 PM EDT

0.2690

+0.01

+(3.38%)

After hours: April 23 at 7:54:52 PM EDT

ADAP 4Q24 Earnings Review: EPS Miss on 1x Restructuring/Impairment Costs; Potential Capital Raise Adds Risk to the Story

By Michael Kim NASDAQ:ADAP READ THE FULL ADAP RESEARCH REPORT After the market closed on 3/24/25, Adaptimmune (NASDAQ:ADAP) filed the company’s Form 10-K Annual Report. ADAP reported a net loss of $74.2 million for 4Q24, or $(0.05) per diluted ordinary share versus our $(0.04) estimate. Relative to our model, the EPS miss was largely a function of non-recurring restructuring costs of $6.0 million

Zacks Small Cap Research 29 days ago

ADAP
-0.80%
Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ...

Adaptimmune Therapeutics PLC (ADAP) reports strong Tecelra launch, operational efficiencies, and strategic cost savings, while addressing future profitability and expansion plans.

GuruFocus.com last month

ADAP
-0.80%
ADAP: 4Q24 Business Update: Tecelra Launch Progressing + Incremental Cost Savings; Banker-Led Process to Explore Strategic Options

By Michael Kim NASDAQ:ADAP Pre-market open on 3/20/25, Adaptimmune (NASDAQ:ADAP) provided a business update for 4Q24 (in lieu of financial results for the quarter/full year to be released in conjunction with the company’s 10-K filing on 3/24/25). From our perspective, key takeaways from ADAP’s 4Q24 business update and management’s quarterly conference call included: 1. Tecelra launch ahead

Zacks Small Cap Research last month

ADAP
-0.80%
Adaptimmune Provides Q4 and Full Year 2024 Business Update

TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programsAt the end of 2024, Adaptimmune had Total Liquidity1 of $152 millionEvaluating all strategic options to maximize shareholder valuePhiladelphia

Newsfile last month

ADAP
-0.80%
From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines

Whether finding new treatments for schizophrenia or first-time ways to tackle bladder cancer, these companies are finding forward-looking therapies.

FastCompany last month

ADAP
-0.80%
PFE
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same ...

Newsfile last month

ADAP
-0.80%
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are retail investors with 50% stake, while 25% is held by hedge funds

Key Insights Adaptimmune Therapeutics' significant retail investors ownership suggests that the key decisions are...

Simply Wall St. last month

ADAP
-0.80%
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February.Guggenheim Securities SMID Cap Biotech Conference, New York, NYFireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m. ESTWebcast link: https://ws

Newsfile 2 months ago

ADAP
-0.80%
Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 86% if they invested five years ago

Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic...

Simply Wall St. 2 months ago

ADAP
-0.80%
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assetsAdaptimmune Allo-T program to be featured at the Biotech ShowCase(TM) and the Wuxi Global Forum 2025Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announ

Newsfile 3 months ago

ADAP
-0.80%
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025Gavin Wood, Chief Financial Officer, will step down from the Company May 31, 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 19, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that two of its executive leadersh

Newsfile 4 months ago

ADAP
-0.80%
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that the first patient has been treated with TECELRA® (afamitresgene autoleucel). TECELRA is the first engineered cell therapy for a soli

Newsfile 4 months ago

ADAP
-0.80%
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Adaptimmune Therapeutics ( NASDAQ:ADAP ) Third Quarter 2024 Results Key Financial Results Revenue: US$40.9m (up 459...

Simply Wall St. 5 months ago

ADAP
-0.80%
Halozyme bids for Evotec; BeiGene gets a new name

The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first Lyfgenia revenue and Leerink built up its M&A team.

BioPharma Dive 5 months ago

HALO

EVT.DE

BGNE
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints

Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

Pharmaceutical Technology 5 months ago

ADAP
-0.80%
GLDAF
ADAP 3Q24 Earnings Review: Streamlining the Platform; Profitability Inflection Point in 2027

By Michael Kim NASDAQ:ADAP READ THE FULL ADAP RESEARCH REPORT Post-market close on 11/13/24, Adaptimmune (NASDAQ:ADAP) reported 3Q24 earnings results. ADAP reported a net loss of $17.6 million for 3Q24, or $(0.01) per diluted ordinary share versus our $(0.03) estimate. Relative to our model, the EPS beat was largely a function of higher revenue (mostly driven by a catch-up adjustment related to

Zacks Small Cap Research 5 months ago

ADAP
-0.80%
Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ...

Adaptimmune Therapeutics PLC (ADAP) outlines a path to operating breakeven by 2027, driven by strategic restructuring and promising outcomes from the IGNYTE-ESO trial.

GuruFocus.com 5 months ago

ADAP
-0.80%
Adaptimmune Reports Q3 2024 Financial and Business Updates

Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS); full data at CTOS conference on November 16Company restructuring to prioritize commercial sarcoma fr

Newsfile 5 months ago

ADAP
-0.80%
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-celResults include six complete responses (6/64); twenty-one partial responses (21/64)Data to be presented at Connective Tissue Oncology Society 2024 Annual Meeting Company plans to initiate a rolling BLA submission for lete-cel for the treatment of advanced or metastatic synovial sarcoma and MRCLS by end of 2025Company to host virtual KOL event Monday, November 18, 2024; 2:30 PM EST featuring ..

Newsfile 5 months ago

ADAP
-0.80%
Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced presence and presentations at key scientific and medical conferences in November and December. Society for Immunotherapy of Cancer (SITC) 39th annual meeting, November 6-10, Houston, TXPodium presentation: "Delivering on the Promise of Cell Therapies for Solid

Newsfile 5 months ago

ADAP
-0.80%

Performance Overview

Return	ADAP	MSCI WORLD (^990100-USD-STRD)
YTD	-53.03%	-4.56%
1-Year	-77.18%	+6.48%
3-Year	-86.23%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Adaptimmune Therapeutics plc (ADAP)

ADAP 4Q24 Earnings Review: EPS Miss on 1x Restructuring/Impairment Costs; Potential Capital Raise Adds Risk to the Story

Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ...

ADAP: 4Q24 Business Update: Tecelra Launch Progressing + Incremental Cost Savings; Banker-Led Process to Explore Strategic Options

Adaptimmune Provides Q4 and Full Year 2024 Business Update

From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are retail investors with 50% stake, while 25% is held by hedge funds

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 86% if they invested five years ago

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Halozyme bids for Evotec; BeiGene gets a new name

Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints

ADAP 3Q24 Earnings Review: Streamlining the Platform; Profitability Inflection Point in 2027

Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ...

Adaptimmune Reports Q3 2024 Financial and Business Updates

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Performance Overview